Actinium
(NYSE: $ATNM) Announces Acceptance of Actimab-A Data for Poster Presentation at
American Society of Hematology Annual Meeting
NEW
YORK - October 19, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals,
Inc. (NYSE: ATNM) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers, announced
today that data from the Company’s Actimab-A program, Actinium's most advanced
alpha particle immunotherapy program intended for newly diagnosed AML patients
over the age of 60, has been selected by the American Society of Hematology
(ASH) Program Committee for poster presentation at the 58th Annual Meeting in
San Diego, California on December 5, 2016.
Title:
Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225
(225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older
with Untreated Acute Myeloid Leukemia (AML)
Abstract:
#4050
Session:
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster
III
Location:
San Diego Convention Center, Hall GH
Presentation:
December 5, 6:00 PM - 8:00 PM
Abstracts
are expected to be available at www.hematology.org on November 3, 2016 at 9:00
am Eastern time. In addition, the abstracts will be published online in the
December 3, 2015 supplemental volume of Blood.
About Actimab-A
Actimab-A,
Actinium's most advanced alpha particle immunotherapy (APIT) program, is in a
Phase 2 clinical trial for patients newly diagnosed with AML over the age of
60. Actimab-A is being developed as a first-line therapy and it has attracted
support from some of the leading experts at the most prestigious cancer
treatment hospitals due to the potential of its safety and efficacy profile.
Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope,
actinium-225. Actinium-225 decays by giving off high-energy alpha particles,
which kill cancer cells. When actinium decays, it produces a series of daughter
atoms, each of which gives off its own alpha particle, increasing the chances
that the cancer cell will be destroyed. HuM195 is the humanized version of M195
and is a monoclonal antibody that targets CD33, which is abundantly found on
myeloid leukemia cells. Both the alpha particle technology and HuM195 were
initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a
second-generation therapy from the Company’s HuM195-Alpha program, which has
now been studied in almost 90 patients in four clinical trials.
About Actinium Pharmaceuticals
Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the
treatment of advanced cancers. Actinium's targeted radioimmunotherapy products
are based on its proprietary delivery platform for the therapeutic utilization
of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's
lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon
approval, in preparing patients for hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. The Company is conducting a
single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or
relapsed AML patients over the age of 55 with a primary endpoint of durable
complete remission. The Company's second product candidate, Actimab-A, is in a
53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed
with AML over the age of 60 in a single-arm multicenter trial
Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.
This
news release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and uncertainties, which
may cause actual results to differ materially from those set forth in the
statements. The forward-looking statements may include statements regarding
product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
Contact:
Steve
O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Source:
Actinium Pharmaceuticals
This news is
published on the Investorideas.com Newswire - a global digital news source for
investors and business leaders
Sign up for free news alerts
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
One month news , social media and marketing Actinium Pharmaceuticals, Inc.
(ATNM) by third party IRTH Communications starting September 19, 2016: three
thousand per month.
No comments:
Post a Comment